Board of Directors
Leadership
Management
Customer Engagement
Professor Rory Shaw
Non-executive Chairman
Professor Rory Shaw was appointed as Non-executive Director, Deputy Chairman and subsequently Chairman of Feedback plc on 29 August 2019. He was previously medical director of Feedback Medical Limited, the Company’s operating subsidiary. During his time with the Company, he has contributed to the development of the Company’s strategy and the vision for Bleepa®. He has played an active part in building relationships with the medical community in the UK and potential customers overseas. Rory is a member of the Remuneration Committee and the Nomination Committee.
Professor Rory Shaw has extensive managerial and overseas trade experience as well as a strong academic and clinical background. Professor Shaw was previously the medical director of Healthcare UK within the Department of International Trade. Over the previous 15 years, he has been medical director of three NHS trusts; North West London Hospitals NHS Trust, the Royal Berkshire NHS Foundation Trust and the Hammersmith Hospital NHS Trust. In 2001, he was appointed by the then minister of health as the first chairman of the National Patient Safety Agency and was also a non-executive director of the NHS Litigation Authority. Professor Shaw’s clinical specialty is respiratory and general medicine. He has been published extensively in academic journals and was also a professor of respiratory medicine at Imperial College School of Medicine. Professor Shaw is also on the Board of the vaccine development company DIOSynVax, and within the NHS, he is the Non-Executive Director for Quality and Performance on the Board of the Bath and NE Somerset, Swindon and Wiltshire Integrated Care System.
Professor Rory Shaw
Non-executive Chairman
Professor Rory Shaw was appointed as Non-executive Director, Deputy Chairman and subsequently Chairman of Feedback plc on 29 August 2019. He was previously medical director of Feedback Medical Limited, the Company’s operating subsidiary. During his time with the Company, he has contributed to the development of the Company’s strategy and the vision for Bleepa®. He has played an active part in building relationships with the medical community in the UK and potential customers overseas. Rory is a member of the Remuneration Committee and the Nomination Committee.
Professor Rory Shaw has extensive managerial and overseas trade experience as well as a strong academic and clinical background. Professor Shaw was previously the medical director of Healthcare UK within the Department of International Trade. Over the previous 15 years, he has been medical director of three NHS trusts; North West London Hospitals NHS Trust, the Royal Berkshire NHS Foundation Trust and the Hammersmith Hospital NHS Trust. In 2001, he was appointed by the then minister of health as the first chairman of the National Patient Safety Agency and was also a non-executive director of the NHS Litigation Authority. Professor Shaw’s clinical specialty is respiratory and general medicine. He has been published extensively in academic journals and was also a professor of respiratory medicine at Imperial College School of Medicine. Professor Shaw is also on the Board of the vaccine development company DIOSynVax, and within the NHS, he is the Non-Executive Director for Quality and Performance on the Board of the Bath and NE Somerset, Swindon and Wiltshire Integrated Care System.
Dr Tom Oakley
Chief Executive Officer
Dr Tom Oakley trained as a Radiology Registrar before becoming an NHS England Clinical Entrepreneur Fellow where he supported a number of companies looking to launch products in the NHS. He joined as CEO of Feedback Medical Limited in February 2019 before being appointed as CEO of Feedback plc on 9 April 2019. Upon joining the Company he led a strategic review of the product portfolio and implemented a pivot away from the company’s traditional low margin, low growth sales to radiology customers, by developing a renewed product range targeted at a wider and underserved clinical audience, where a new pricing model of recurring SaaS revenue was initiated. These new products include Bleepa®, a secure clinical communication and data viewing platform and CareLocker®, a patient-centric cloud architecture that achieves new levels of secure data portability.
Tom has led the Company through three successful funding rounds raising approximately £18.5m to stimulate the development and launch of Bleepa® and CareLocker®, taking these products from concept to contracts in multiple NHS sites and with a key veterinary sector partner. Under his leadership the Company has achieved its pivot within three years, now recognising strong revenue growth with a number of scale opportunities in both domestic and international markets.
Dr Tom Oakley
Chief Executive Officer
Dr Tom Oakley trained as a Radiology Registrar before becoming an NHS England Clinical Entrepreneur Fellow where he supported a number of companies looking to launch products in the NHS. He joined as CEO of Feedback Medical Limited in February 2019 before being appointed as CEO of Feedback plc on 9 April 2019. Upon joining the Company he led a strategic review of the product portfolio and implemented a pivot away from the company’s traditional low margin, low growth sales to radiology customers, by developing a renewed product range targeted at a wider and underserved clinical audience, where a new pricing model of recurring SaaS revenue was initiated. These new products include Bleepa®, a secure clinical communication and data viewing platform and CareLocker®, a patient-centric cloud architecture that achieves new levels of secure data portability.
Tom has led the Company through three successful funding rounds raising approximately £18.5m to stimulate the development and launch of Bleepa® and CareLocker®, taking these products from concept to contracts in multiple NHS sites and with a key veterinary sector partner. Under his leadership the Company has achieved its pivot within three years, now recognising strong revenue growth with a number of scale opportunities in both domestic and international markets.
Anesh Patel
Chief Financial Officer
Anesh started his career with Ernst & Young in 2004 where he qualified as a Chartered Accountant, initially working in the audit & assurance division before transferring to the transaction support team for private equity clients. Prior to joining the Group in April 2021, Anesh held the position of Finance & Corporate Projects Director of hVIVO Limited, the main trading subsidiary of AIM-listed Open Orphan plc and a rapidly growing, industry-leading, clinical services provider to pharma, biotech and government organisations.
Anesh also has seven years of investment banking experience where he specialised in corporate finance advisory services for leading institutions Standard Bank and Société Générale, advising on a range of strategic transactions including public and private M&A and capital-raising. He graduated from University College London (UCL) and holds an M.Sci. (Hons) degree in Mathematics with Economics. Since joining the Group, Anesh has optimised finance systems and processes to facilitate growth and the evolution to a recurring SAAS-based revenue model, and he co-led an oversubscribed equity fundraise of £11.2m in November 2021.
Anesh Patel
Chief Financial Officer
Anesh started his career with Ernst & Young in 2004 where he qualified as a Chartered Accountant, initially working in the audit & assurance division before transferring to the transaction support team for private equity clients. Prior to joining the Group in April 2021, Anesh held the position of Finance & Corporate Projects Director of hVIVO Limited, the main trading subsidiary of AIM-listed Open Orphan plc and a rapidly growing, industry-leading, clinical services provider to pharma, biotech and government organisations.
Anesh also has seven years of investment banking experience where he specialised in corporate finance advisory services for leading institutions Standard Bank and Société Générale, advising on a range of strategic transactions including public and private M&A and capital-raising. He graduated from University College London (UCL) and holds an M.Sci. (Hons) degree in Mathematics with Economics. Since joining the Group, Anesh has optimised finance systems and processes to facilitate growth and the evolution to a recurring SAAS-based revenue model, and he co-led an oversubscribed equity fundraise of £11.2m in November 2021.
Annemijn Eschauzier
Non-executive Director
Annemijn is a strategic marketing leader and brings significant global leadership experience with a career spanning over 25 years in the healthcare sector. She started her career at GlaxoSmithKline before moving to GE Healthcare, where she held a variety of leadership positions for over 15 years becoming Chief Marketing Officer Women’s Health in September 2017.
Since leaving GE Healthcare in 2021, Annemijn has joined Hardian Health, a company which provides strategic services to navigate the digital health sector. In addition, Annemijn holds other non-statutory Board member roles. Annemijn is Chair of the Remuneration Committee, a member of the Audit Committee and a member of the Nomination Committee.
Annemijn Eschauzier
Non-executive Director
Annemijn is a strategic marketing leader and brings significant global leadership experience with a career spanning over 25 years in the healthcare sector. She started her career at GlaxoSmithKline before moving to GE Healthcare, where she held a variety of leadership positions for over 15 years becoming Chief Marketing Officer Women’s Health in September 2017.
Since leaving GE Healthcare in 2021, Annemijn has joined Hardian Health, a company which provides strategic services to navigate the digital health sector. In addition, Annemijn holds other non-statutory Board member roles. Annemijn is Chair of the Remuneration Committee, a member of the Audit Committee and a member of the Nomination Committee.
Adam Denning
Non-executive Director
Adam currently serves as a non-executive director at Investors in People and Finlight.com, in addition to his role at Feedback plc. He’s also a trustee at the Ben Uri Museum and Gallery, and managing director of Logical Operators Limited. Previously, he spent 25 years at Microsoft Corporation in various predominantly technical roles. From 2011- 2017, he was a partner group program manager in Windows. In this role, he reported directly to the corporate VP of the platform, leading an international team of over 100 people and executing updates to Windows to deliver new customers.
Before then, from 1999-2001, he served as the assistant technical advisor to the Executive Office. Among other responsibilities, Adam presented “demo days”, where he would demonstrate internal and external technology to Bill Gates and would attend all of his product reviews. Adam is a member of the Audit Committee, the Remuneration Committee and the Nomination Committee.
Adam Denning
Non-executive Director
Adam currently serves as a non-executive director at Investors in People and Finlight.com, in addition to his role at Feedback plc. He’s also a trustee at the Ben Uri Museum and Gallery, and managing director of Logical Operators Limited. Previously, he spent 25 years at Microsoft Corporation in various predominantly technical roles. From 2011- 2017, he was a partner group program manager in Windows. In this role, he reported directly to the corporate VP of the platform, leading an international team of over 100 people and executing updates to Windows to deliver new customers.
Before then, from 1999-2001, he served as the assistant technical advisor to the Executive Office. Among other responsibilities, Adam presented “demo days”, where he would demonstrate internal and external technology to Bill Gates and would attend all of his product reviews. Adam is a member of the Audit Committee, the Remuneration Committee and the Nomination Committee.
Philipp Prince
Non-executive Director
Philipp is a chartered accountant with extensive experience in senior finance roles in both private and listed technology companies. He is the Group CFO and board member of BCB Group Holdings Ltd, a digital banking challenger. He was previously a board adviser at Overmore Limited, a marketing technology firm, the CFO of Defenx plc, an AIM-listed mobile cyber security company, where he managed the IPO process, fundraising and investor relations and Interim CFO at Enecsys plc, a private equity backed solar micro-inverter developer. For over 20 years, Philipp worked at BDO LLP, where he was a corporate finance partner from 2002-2013.
Philipp chairs the Audit Committee and is a member of the Remuneration Committee and the Nomination Committee.
Philipp Prince
Non-executive Director
Philipp is a chartered accountant with extensive experience in senior finance roles in both private and listed technology companies. He is the Group CFO and board member of BCB Group Holdings Ltd, a digital banking challenger. He was previously a board adviser at Overmore Limited, a marketing technology firm, the CFO of Defenx plc, an AIM-listed mobile cyber security company, where he managed the IPO process, fundraising and investor relations and Interim CFO at Enecsys plc, a private equity backed solar micro-inverter developer. For over 20 years, Philipp worked at BDO LLP, where he was a corporate finance partner from 2002-2013.
Philipp chairs the Audit Committee and is a member of the Remuneration Committee and the Nomination Committee.